(Press-News.org) A recent clinical trial found that interferonβ-1a (INF) and glatiramer acetate (GA), two of the most commonly prescribed drugs for multiple sclerosis (MS), provide no additional clinical benefit when taken together. While findings published today in Annals of Neurology, a journal of the American Neurological Association and Child Neurology Society, suggest that taking both INF and GA together was not superior to GA monotherapy in reducing relapse risk; the combination therapy does appear to reduce new lesion activity and total lesion volume.
The National Institute of Neurological Disorders and Stroke (NINDS) describes MS as a neuroinflammatory disease, which affects the central nervous system by attacking myelin, a substance found in nerve fibers. NINDS estimates that up to 350,000 individuals in the U.S. are diagnosed with MS, which affects twice as many women as men, with most symptoms appearing between the ages of 20 and 40. Experts believe this complex autoimmune disease may be caused by genetic and environmental factors.
"While there are a number of drugs to treat MS, our study is the first to investigate if the concurrent use of two drugs with different modes of action would provide any additional clinical benefit without side effects," explains lead author Dr. Fred Lublin, Director of the Corinne Goldsmith Dickinson Center for Multiple Sclerosis at Mount Sinai Medical Center in New York. "The CombiRx study was designed to assess whether IFN and GA in combination was more effective than either alone in reducing relapse of MS."
The research team enrolled 1,008 participants from 68 sites in this double-blind, randomized, controlled phase III trial. Participants received IFN plus GA (499), IFN alone (250), or GA alone (259), with 30µg IFN administered intramuscularly weekly and/or 20 mg of GA injected daily. The groups were followed for three years to assess if the combination therapy reduced MS relapse rates.
Trial results found that the IFN plus GA combination did not lessen disease progression according to the Expanded Disability Status Scale (a measure of disability caused by MS) or show change in the Multiple Sclerosis Functional Composite (measure used during clinical trials to assess leg, arm, and cognitive function in MS patients) better than the individual agents over a three-year period. The combination therapy and GA alone were significantly better than IFN in reducing relapse risk. MRI findings also suggested that the IFN plus GA together were better in reducing new lesions (plaques) and total lesion accumulation than either drug alone.
Dr. Lublin concludes, "Combining two of the most commonly prescribed MS therapies did not produce significant clinical benefit, reducing relapse risk, during the three-year study period. We will continue to monitor this group to determine if the combination therapy displays positive results, particularly in reducing lesion activity, beyond the initial trial timeframe."
In a related editorial, Dr. Stephen L. Hauser, Department of Neurology Chair at University of California, San Francisco and Editor-in-Chief of Annals adds, "In the end, CombiRx was essentially a negative study, with the combination therapy doing no better than monotherapy in reducing MS relapse rate over three years. However, the continued follow-up of this group by Dr. Lublin and colleagues provides an opportunity to develop a comprehensive long-term history of MS—assessing response to first-generation therapies, possibly predicting individual disease trajectories, and understanding of treatment response. CombiRx could emerge as a model for long-term assessment, not only in MS, but across clinical neuroscience."
###
This CombiRx study was funded by a grant from the NINDS—a part of the National Institutes of Health.
This study is published in Annals of Neurology. Media wishing to receive a PDF of this article may contact sciencenewsroom@wiley.com
Full citation: "Randomized Study Combining Interferon and Glatiramer Acetate in Multiple Sclerosis." Fred D. Lublin, Stacey S. Cofield, Gary R. Cutter, Robin Conwit, Ponnada A. Narayana, Flavia Nelson, Amber R. Salter, Tarah Gustafson and Jerry S. Wolinsky for the CombiRx Investigators. Annals of Neurology; Published March, 2013 (DOI:10.1002/ana.23863).
URL: http://doi.wiley.com/10.1002/ana.23863
Author Contact: To arrange an interview with Dr. Lublin, please contact Christie Corbett with Mount Sinai Medical Center christie.corbett@mountsinai.org.
About the Journal
Annals of Neurology, the official journal of the American Neurological Association and the Child Neurology Society, publishes articles of broad interest with potential for high impact in understanding the mechanisms and treatment of diseases of the human nervous system. All areas of clinical and basic neuroscience, including new technologies, cellular and molecular neurobiology, population sciences, and studies of behavior, addiction, and psychiatric diseases are of interest to the journal. The journal is published by Wiley on behalf of the American Neurological Association and Child Neurology Society. For more information, please visit http://onlinelibrary.wiley.com/journal/10.1002/ana.
About Wiley
Wiley is a global provider of content-enabled solutions that improve outcomes in research, education, and professional practice. Our core businesses produce scientific, technical, medical, and scholarly journals, reference works, books, database services, and advertising; professional books, subscription products, certification and training services and online applications; and education content and services including integrated online teaching and learning resources for undergraduate and graduate students and lifelong learners.
Founded in 1807, John Wiley & Sons, Inc. (NYSE: JWa, JWb), has been a valued source of information and understanding for more than 200 years, helping people around the world meet their needs and fulfill their aspirations. Wiley and its acquired companies have published the works of more than 450 Nobel laureates in all categories: Literature, Economics, Physiology or Medicine, Physics, Chemistry, and Peace. Wiley's global headquarters are located in Hoboken, New Jersey, with operations in the U.S., Europe, Asia, Canada, and Australia. The Company's website can be accessed at http://www.wiley.com.
END
A pair of newly discovered stars is the third-closest star system to the Sun, according to a paper that will be published in Astrophysical Journal Letters. The duo is the closest star system discovered since 1916. The discovery was made by Kevin Luhman, an associate professor of astronomy and astrophysics at Penn State University and a researcher in Penn State's Center for Exoplanets and Habitable Worlds.
Both stars in the new binary system are "brown dwarfs," which are stars that are too small in mass to ever become hot enough to ignite hydrogen fusion. As a result, ...
Philadelphia, PA, March 11, 2013 – Antipsychotic administration in the elderly is associated with an increased risk for cerebrovascular accident, more commonly known as stroke; a new study published in Biological Psychiatry provides additional insight into this important relationship.
Antipsychotics are prescribed to elderly patients to treat symptoms such as agitation, psychosis, anxiety, insomnia, and depression. The increased risk of stroke associated with these medications was identified approximately a decade ago and has since been replicated by subsequent studies. ...
It may be better to tolerate lower oil content in algae grown for biodiesel to boost growth and overall productivity, says research from the University of Sheffield.
The research shows that the commonly accepted method of depriving algae of key nutrients such as nitrogen in order to boost its oil content may be detrimental to overall oil yield in the long term.
"Total oil production depends not just on the oil content of the algal cells but how quickly the cells grow and multiply," says Dr Stephen Wilkinson of the University's Department of Chemical and Biological ...
Philadelphia, Pa. (March 11, 2013) – Members of the Deaf community who suffer from mental health problems need culturally sensitive treatment to avoid misdiagnosis and inappropriate treatment, according to a report in the March Journal of Psychiatric Practice. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.
"Deaf individuals comprise a cultural and linguistic minority group within the United States, and culturally and linguistically appropriate psychiatric treatment must reflect these differences," according to Sarah A. Landsberger, ...
When it comes to body shape, diet and exercise can only take us so far. Our body shape and geometry are largely determined by genetic factors. Genetics also have an impact on our body composition – including soft fat tissue and hard bone tissue – and can lead to excess fat or osteoporosis.
Now Prof. Gregory Livshits of Tel Aviv University's Department of Anatomy and Anthropology at the Sackler Faculty of Medicine, working alongside Dr. Michael Korostishevsky, has uncovered a clear genetic link between fat and bone mass. These factors, which contribute to bone metabolism, ...
WASHINGTON, DC, March 11, 2013 — Research has long linked high socioeconomic status with better health and lower mortality. But what's remained unclear is whether this association has more to do with access to resources (education, wealth, career opportunity, etc.) or the glow of high social status relative to others. Scholars call the latter "relative deprivation."
To tease apart these factors, a team of investigators at Columbia University's Mailman School of Public Health led by Dr. Bruce Link, studied Baseball Hall of Fame inductees, Emmy Award winners, and former ...
SAN FRANCISCO — Heart patients who can't tolerate the side effects of cholesterol-lowering drugs may have a new option, according to a new study by researchers from the Intermountain Heart Institute at Intermountain Medical Center in Salt Lake City.
Researchers found that pitavastatin, a newer cholesterol-lowering drug, may reduce the risk of heart attack, stroke and even death in up to 68 percent of patients with high cholesterol who can't tolerate other cholesterol-lowering medications due to side effects.
Researchers are presenting the results of this study today ...
All living organisms rely on iron as an essential nutrient. In the ocean, iron's abundance or scarcity means all the difference as it fuels the growth of plankton, the base of the ocean's food web.
A new study by biogeochemists and glaciologists at Woods Hole Oceanographic Institution (WHOI) identifies a unexpectedly large source of iron to the North Atlantic – meltwater from glaciers and ice sheets, which may stimulate plankton growth during spring and summer. This source is likely to increase as melting of the Greenland ice sheet escalates under a warming climate.
The ...
Their warning comes as the Chief Medical Officer launches the UK's Antimicrobial Resistance Strategy and Action Plan, reflecting the need for a clear change in our understanding of and response to antimicrobial resistance by the public, NHS and government.
Current estimates suggest that antibiotic resistance is a relatively cheap problem, they write, but such estimates do not take account of the fact that antimicrobial medicines are integral to modern healthcare. For example, antibiotics are given as standard to patients undergoing surgery, to women delivering by caesarean ...
March 11, 2013 -- Research has long linked high socioeconomic status with better health and lower mortality. But what's remained unclear is whether this association has more to do with access to resources (education, wealth, career opportunity, etc.) or the glow of high social status relative to others. Scholars call the latter "relative deprivation."
To tease apart these factors, a team of investigators at Columbia University's Mailman School of Public Health led by Dr. Bruce Link, studied Baseball Hall of Fame inductees, Emmy Award winners, and former Presidents and ...
